Search

Your search keyword '"Brice, Pauline"' showing total 17 results
Start Over Author "Brice, Pauline" Journal leukemia & lymphoma
17 results on '"Brice, Pauline"'

1. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study

Author

Stamatoullas, Aspasia, primary, Ghesquières, Hervé, additional, Feugier, Pierre, additional, André, Marc, additional, Le Bras, Fabien, additional, Gac, Anne-Claire, additional, Borel, Cécile, additional, Gastinne, Thomas, additional, Quittet, Philippe, additional, Morschhauser, Franck, additional, Ribrag, Vincent, additional, Guidez, Stephanie, additional, Nicolas-Virelizier, Emmanuelle, additional, Berriolo-Riedinger, Alina, additional, Vander Borght, Thierry, additional, Edeline, Véronique, additional, and Brice, Pauline, additional

Published
2022
Full Text
View/download PDF

2. Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis

Author

Zinzani, Pier Luigi, primary, Chen, Robert, additional, Armand, Philippe, additional, Johnson, Nathalie A., additional, Brice, Pauline, additional, Radford, John, additional, Ribrag, Vincent, additional, Molin, Daniel, additional, Vassilakopoulos, Theodoros P., additional, Tomita, Akihiro, additional, von Tresckow, Bastian, additional, Shipp, Margaret A., additional, Lin, Jianxin, additional, Nahar, Akash, additional, Balakumaran, Arun, additional, and Moskowitz, Craig H., additional

Published
2020
Full Text
View/download PDF

3. Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC

Author

Garciaz, Sylvain, primary, Loschi, Mickael, additional, De Masson, Adèle, additional, Biard, Lucie, additional, Mercier, Mélanie, additional, Tomowiak, Cécile, additional, Delage, Jeremy, additional, Labussiere-Wallet, Hélène, additional, Sibon, David, additional, Cassuto, Ophélie, additional, Borel, Cécile, additional, Cornillon, Jérome, additional, Nimubona, Stanislas, additional, Charbonnier, Amandine, additional, Brice, Pauline, additional, Socié, Gérard, additional, Bouabdallah, Reda, additional, de Latour, Régis Peffault, additional, and de Fontbrune, Flore Sicre, additional

Published
2019
Full Text
View/download PDF

4. Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

Author

von Tresckow, Bastian, primary, Fanale, Michelle, additional, Ardeshna, Kirit M., additional, Chen, Robert, additional, Meissner, Julia, additional, Morschhauser, Franck, additional, Moskowitz, Craig, additional, Zinzani, Pier Luigi, additional, Giezek, Hilde, additional, Balakumaran, Arun, additional, Vo, Thao T., additional, Raut, Monika, additional, and Brice, Pauline, additional

Published
2019
Full Text
View/download PDF

6. Management of relapsed or refractory follicular lymphoma patients in daily practice – a French non-interventional study

Author

Feugier, Pierre, primary, Brice, Pauline, additional, Maynadié, Marc, additional, Franchi-Rezgui, Patricia, additional, Hacini, Maya, additional, Laurent, Guy, additional, Suc, Etienne, additional, Fitoussi, Olivier, additional, Solal-Celigny, Philippe, additional, Damaj, Ghandi, additional, Haioun, Corinne, additional, Leconte, Pierre, additional, Lazreg, Fatima, additional, Boissard, Frédéric, additional, Pau, David, additional, and Salles, Gilles, additional

Published
2018
Full Text
View/download PDF

7. Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies

Author

Pilorge, Sylvain, primary, Harel, Stephanie, additional, Ribrag, Vincent, additional, Larousserie, Frédérique, additional, Willems, Lise, additional, Franchi, Patricia, additional, Legoff, Marielle, additional, Biau, David, additional, Anract, Philippe, additional, Roux, Christian, additional, Blanc-Autran, Estelle, additional, Delarue, Richard, additional, Gisselbrecht, Christian, additional, Ketterer, Nicolas, additional, Recher, Christian, additional, Bonnet, Christophe, additional, Peyrade, Frederic, additional, Haioun, Corinne, additional, Tilly, Hervé, additional, Salles, Gilles, additional, Brice, Pauline, additional, Bouscary, Didier, additional, Deau, Bénédicte, additional, and Tamburini, Jerome, additional

Published
2016
Full Text
View/download PDF

9. Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study

Author

Fleury, Isabelle, primary, Amorim, Sandy, additional, Mounier, Nicolas, additional, Coiffier, Bertrand, additional, Dupuis, Jehan, additional, Tilly, Hervè, additional, Mazari, Mohamed A., additional, Filliatre, Lauriane, additional, Brière, Josette, additional, Brice, Pauline, additional, de Kerviler, Eric, additional, and Thieblemont, Catherine, additional

Published
2014
Full Text
View/download PDF

10. Subacute inflammatory demyelinating polyradiculoneuropathy complicating relapsing Hodgkin lymphoma: another immune-related adverse event of the anti-PD1 therapy?

Author

Barp, Andrea, Delorme, Cécile, Viala, Karine, Lenglet, Timothée, Bernard, Sophie, Brice, Pauline, Gilardin, Laurent, Afanasiev, Vadim, and Psimaras, Dimitri

Subjects
HODGKIN'S disease, ADVERSE health care events, DRUG side effects, GRAFT versus host disease, MEDICAL research
Abstract

The article focuses on the immune checkpoint inhibitor (ICI) named Pembrolizumab for adults with refractory classical Hodgkin lymphoma (HL). It discusses the initial therapies with mechlorethamine, vincristine, procarbazine and prednisone (MOPP) and doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD).

Published
2019
Full Text
View/download PDF

11. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment

Author

Lenglet, Julien, primary, Traullé, Catherine, additional, Mounier, Nicolas, additional, Benet, Claire, additional, Munoz-Bongrand, Nicolas, additional, Amorin, Sandy, additional, Noguera, Maria-Elena, additional, Traverse-Glehen, Alexandra, additional, Ffrench, Martine, additional, Baseggio, Lucile, additional, Felman, Pascale, additional, Callet-Bauchu, Evelyne, additional, Brice, Pauline, additional, Berger, Françoise, additional, Salles, Gilles, additional, Brière, Josette, additional, Coiffier, Bertrand, additional, and Thieblemont, Catherine, additional

Published
2014
Full Text
View/download PDF

12. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients

Author

Ghesquières, Hervé, primary, Stamatoullas, Aspasia, additional, Casasnovas, Olivier, additional, Morschhauser, Franck, additional, Gyan, Emmanuel, additional, Gabarre, Jean, additional, Malphettes, Marion, additional, Clément, Laurence, additional, Ferlay, Céline, additional, and Brice, Pauline, additional

Published
2013
Full Text
View/download PDF

13. Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study.

Author

Fleury, Isabelle, Amorim, Sandy, Mounier, Nicolas, Coiffier, Bertrand, Dupuis, Jehan, Tilly, Hervè, Mazari, Mohamed A., Filliatre, Lauriane, Brière, Josette, Brice, Pauline, de Kerviler, Eric, and Thieblemont, Catherine

Subjects
B cells, HODGKIN'S disease, SPINAL cord, HUMORAL immunity, LYMPHOCYTES
Abstract

Initial spinal cord compression (ISCC) in B-cell non-Hodgkin lymphoma (NHL) is rarely present at diagnosis. We performed a multicenter retrospective analysis of 66 patients with ISCC, including diffuse large B-cell (DLBCL) (70%), follicular (20%), small lymphocytic (6%), marginal zone (2%) and B-cell unclassified (2%) lymphomas, with the aim of describing their management and outcomes, as well as the occurrence of central nervous system (CNS) relapses. All but two patients received cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or CHOP-like regimens, with rituximab in 61% of cases. Forty-six patients received CNS prophylaxis. The 5-year overall survival and progression-free survival were 78% and 65% for DLBCL, and 60% and 48% for indolent lymphomas, respectively. CNS relapses occurred in four (6%) patients, all with DLBCL and all in the cerebellum. Initial decompressive procedures, intradural involvement, cerebrospinal fluid infiltration and lack of CNS prophylaxis did not influence survival. Adverse prognostic factors were male sex, poor performance status, elevated lactate dehydrogenase and high age-adjusted international prognostic index. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

15. Hematologic Recovery and Survival of Lymphoma Patients After Autologous Stem-Cell Transplantation: Comparison of Bone Marrow and Peripheral Blood Progenitor Cells

Author

Brice, Pauline, primary, Marolleau, Jean Pierre, additional, Pautier, Patricia, additional, Makke, Jaafar, additional, Cazals, Dominique, additional, Dombret, Hervé, additional, FranÇOise D'Agay, Marie, additional, Benbunan, Marc, additional, and Gisselbrecht, Christian, additional

Published
1996
Full Text
View/download PDF

16. A Multicentric Randomised Study of Alpha 2b Interferon (IFN) and Hydroxyurea (HU) with or without Cytosine-Arabinoside (Ara-c) in Previously Untreated Patients with Ph+ Chronic Myelocytic Leukemia (CML): Preliminary Cytogenetic Results

Author

Guilhot, Francois, primary, Abgrall, Jean-Francois, additional, Harousseau, Jean-Luc, additional, Bauters, Francis, additional, Brice, Pauline, additional, Dine, Gerard, additional, Tilly, Herve, additional, Ifrahy, Norbert, additional, Cassasus, Philippe, additional, Rochant, Henri, additional, Christian, Bernard, additional, Guerci, Agnes, additional, Lamagnere, Jean-Pierre, additional, Prise, Pierre-Yves Le, additional, Duclos, Brigitte, additional, and Tanzer, Joseph, additional

Published
1993
Full Text
View/download PDF

17. A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: Results of a phase II study of the Groupe d'Études des Lymphomes de l'Adulte (GELA).

Author

Fermé, Christophe, Brice, Pauline, Michallet, Anne-Sophie, Lederlin, Pierre, Diviné, Marine, Casasnovas, Olivier, Devidas, Alain, Anglaret, Bruno, Cazals-Hatem, Dominique, Mounier, Nicolas, and for the Groupe d'Études des Lymphomes de l'Adulte, Hôpital Saint-Louis, Paris, France

Subjects
*HODGKIN'S disease treatment, *DOXORUBICIN, *ANTHRACYCLINES, *LYMPHOMA treatment, *RETICULOENDOTHELIAL granulomas, *LYMPHOPROLIFERATIVE disorders, *THERAPEUTICS
Abstract

This multicenter phase II study assessed the feasibility and efficacy of a weekly chemotherapy regimen with a moderately escalated dose of doxorubicin administered over 16 weeks, followed by radiation therapy (RT) to bulky sites. From July 1996 to February 1998, 44 untreated patients with stage IIIB-IV Hodgkin's lymphoma (HL), and 0 - 2 risk factors described by the Memorial Sloan-Kettering Cancer Center, were treated. Chemotherapy was a combination of increased-dose doxorubicin with conventional doses of cyclophosphamide, vinblastine, prednisone, vindesine, bleomycin, and etoposide. Patients received four cycles of the weekly regimen for 16 weeks. Forty-one patients received the planned four cycles of chemotherapy, and RT was delivered to 36 patients. The incidence of WHO grade 3 - 4 neutropenia was 90%. A total of 39 patients achieved a complete remission (88.6%). The median follow-up was 95 months. The 7-years freedom from treatment failure and overall survival estimates were 57% (95% confidence interval (CI), 41% - 70%), and 93% (95% CI, 80 - 98%), respectively. The relapse rate was related to the short duration of chemotherapy, and the failure to prevent relapses with consolidation RT. In this study population the 16-week regimen and RT to bulky sites were not sufficient for disease control. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results